Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Elusys Receives Anthrax Contract

by Ann M. Thayer
January 11, 2010 | A version of this story appeared in Volume 88, Issue 2

New Jersey-based Elusys Therapeutics could get up to $143 million in Department of Health & Human Services funding to complete the development, commercial manufacture, and regulatory approval of Anthim, a monoclonal antibody designed to prevent and treat inhalation anthrax. Anthim targets the protective antigens of Bacillus anthracis and neutralizes anthrax toxins. Elusys will get $16.8 million in the first year of the five-year contract. The company has already received $34 million in government funding to develop the antibody.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.